<DOC>
	<DOCNO>NCT01861444</DOCNO>
	<brief_summary>This prospective , multicenter , observational study assess prevalence chronic hepatitis D patient chronic hepatitis B Romania evaluate efficacy Pegasys ( peginterferon alfa-2a ) patient chronic hepatitis D. Eligible patient treat Pegasys accord current medical practice follow 24 week end treatment .</brief_summary>
	<brief_title>An Observational Study Prevalence Chronic Hepatitis D Romania Efficacy Treatment With Pegasys ( Peginterferon Alfa-2a )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<mesh_term>Hepatitis D , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>For epidemiological part study : Adult patient &gt; /= 18 year age Positive HBsAg least 6 month For noninterventional section study Adult patient , &gt; /= 18 year age Positive HBsAg least 6 month Positive antidelta positive HDV RNA PCR Elevated serum ALT &gt; /= 2x ULN Patients follow eligible treatment Pegasys : History neurological disease History severe psychiatric disease Decompensated diabetes History immunologically mediate disease History severe cardiac disease History evidence severe chronic pulmonary disease Inadequate hematologic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>